

Supplemental Material

Table S1. Effect of intensive versus standard BP lowering on 1-year change hs-cTnT stratified by baseline combined DBP and hs-cTnT categories.

| Baseline DBP category | Treatment arm | GMR (95% CI) | P for interaction |
|------------------------------|----------------------|---------------------|--------------------------|
| DBP \geq 70 | Intensive | 1.04 (1.02, 1.06) | 0.51 |
| | Standard | Reference | |
| DBP <70 + hs-cTnT <14 | Intensive | 1.05 (1.01, 1.09) | |
| | Standard | Reference | |
| DBP <70 + hs-cTnT \geq 14 | Intensive | 1.01 (0.95, 1.08) | |
| | Standard | Reference | |

CI, confidence interval; CVD, cardiovascular disease; DBP, diastolic blood pressure; GMR, geometric mean ratio; hs-cTnT, high sensitivity cardiac troponin T; IQR, interquartile range; SBP, systolic blood pressure.


*Models adjust for baseline hs-cTnT.

Table S2. Effect of intensive versus standard BP lowering on the CVD composite endpoint and all-cause death stratified by baseline combined PP and hs-cTnT categories and combined DBP and CVD categories.

| | Standard BP lowering Events/Total No. (%) | Intensive BP lowering Events/Total No. (%) | HR (95% CI) | <i>P</i> for interaction |
|----------------------------|--|---|-------------------|--------------------------|
| PP and hs-cTnT | | | | |
| CVD composite | | | | |
| PP ≤70 | 223/3311 (6.7%) | 155/3296 (4.7%) | 0.69 (0.56, 0.84) | 0.58 |
| PP >70 + hs-cTnT <14 | 52/703 (7.4%) | 38/721 (5.3%) | 0.70 (0.46, 1.07) | |
| PP >70 + hs-cTnT ≥14 | 62/397 (15.6%) | 53/400 (13.3%) | 0.86 (0.60, 1.25) | |
| All-cause death | | | | |
| PP ≤70 | 134/3311 (4.1%) | 81/3296 (2.5%) | 0.60 (0.46, 0.79) | 0.09 |
| PP >70 + hs-cTnT <14 | 22/703 (3.1%) | 27/721 (3.7%) | 1.20 (0.68, 2.10) | |
| PP >70 + hs-cTnT ≥14 | 49/397 (12.3%) | 38/400 (9.5%) | 0.78 (0.51, 1.19) | |
| DBP and CVD | | | | |
| CVD composite | | | | |
| DBP ≥70 | 230/3380 (6.8%) | 169/3377 (5.0%) | 0.73 (0.60, 0.89) | 0.87 |
| DBP <70 + no prevalent CVD | 61/729 (8.4%) | 42/744 (5.7%) | 0.66 (0.44, 0.98) | |
| DBP <70 + prevalent CVD | 46/302 (15.2%) | 35/296 (11.8%) | 0.76 (0.49, 1.17) | |
| All-cause death | | | | |
| DBP ≥70 | 140/3380 (4.1%) | 91/3377 (2.7%) | 0.65 (0.50, 0.84) | 0.31 |
| DBP <70 + no prevalent CVD | 38/729 (5.2%) | 38/744 (5.1%) | 0.96 (0.61, 1.51) | |
| DBP <70 + prevalent CVD | 27/302 (8.9%) | 17/296 (5.7%) | 0.65 (0.35, 1.19) | |


CI, confidence interval; CVD, cardiovascular disease; DBP, diastolic blood pressure; HR, hazard ratio; hs-cTnT, high sensitivity cardiac troponin T; PP, pulse pressure; SBP, systolic blood pressure.

Figure S1. Cumulative incidence of primary CVD composite endpoint stratified by baseline combined DBP and hs-cTnT categories.



The composite CVD outcome includes nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, nonfatal acute decompensated heart failure, stroke, and death from CVD. Baseline categories include: (1) DBP \geq 70 mm Hg; (2) DBP <70 mm Hg and hs-cTnT <14 ng/L; (3) DBP <70 mm Hg and hs-cTnT \geq 14 ng/L. DBP indicates diastolic blood pressure; hs-cTnT, high sensitivity cardiac troponin T.

Figure S2. Effect of intensive versus standard BP lowering on the non-stroke CVD composite endpoint stratified by baseline combined DBP and hs-cTnT categories.



The non-stroke composite CVD outcome includes nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, nonfatal acute decompensated heart failure, and death from CVD. HRs were obtained from multivariable Cox proportional hazards models that included age, sex, race, treatment assignment, current smoking, prior cardiovascular disease, body mass index, low density lipoprotein cholesterol, systolic blood pressure, statin use, total number of antihypertensive medications, and estimated glomerular filtration rate. DBP indicates diastolic blood pressure; HR, hazard ratio; hs-cTnT, high sensitivity cardiac troponin T; SBP, systolic blood pressure.